New combo therapy shows promise for kids with Hard-to-Treat melanoma
NCT ID NCT00539591
First seen Jan 07, 2026 · Last updated Jun 14, 2026 · Updated 25 times
Summary
This study tested a combination of two drugs, temozolomide and peginterferon, in children and young adults up to age 21 with advanced or recurrent melanoma that cannot be removed by surgery. The main goal was to see how well the tumors responded to treatment and to check for side effects. The trial enrolled 29 participants and is no longer recruiting new patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rady Children's Hospital
San Diego, California, 92123, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
The Children's Cancer Hospital at UT M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.